Concepedia

Megan D. Kok

MD

Statistics

Publications

2

Citations

89

H-Index

2

Active since

2017

Affiliations

AstraZeneca (Netherlands)(Current)

Megan D. Kok is an author at AstraZeneca (Netherlands) specializing in blood pressure, type 2 diabetes pharmacotherapy, and medicine.

Publications per year

2017–2022

2

Publications

2

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok et al. · Cardiovascular Diabetology · 2022 · 54 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up

John Wilding, Clifford J. Bailey, Una Rigney et al. · Primary care diabetes · 2017 · 35 citations

Medicine, Internal Medicine, Pharmacotherapy +15

1–2 of 2